Ultragenyx Pharmaceutical Balance Sheet Health
Financial Health criteria checks 1/6
Ultragenyx Pharmaceutical has a total shareholder equity of $140.3M and total debt of $891.4M, which brings its debt-to-equity ratio to 635.5%. Its total assets and total liabilities are $1.3B and $1.2B respectively.
Key information
635.5%
Debt to equity ratio
US$891.41m
Debt
Interest coverage ratio | n/a |
Cash | US$412.08m |
Equity | US$140.26m |
Total liabilities | US$1.17b |
Total assets | US$1.31b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: UP0's short term assets ($596.0M) exceed its short term liabilities ($245.6M).
Long Term Liabilities: UP0's short term assets ($596.0M) do not cover its long term liabilities ($921.2M).
Debt to Equity History and Analysis
Debt Level: UP0's net debt to equity ratio (341.7%) is considered high.
Reducing Debt: UP0's debt to equity ratio has increased from 0% to 635.5% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: UP0 has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: UP0 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 12.9% each year